GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Company Participants
Max Gadicke - Stern, IR
David Dodd - Chairman and CEO
Mark Reynolds - CFO
Kelly McKee - Chief Medical Officer
John Sharkey - VP, Business Development
Conference Call Participants
Laura Suriel - Alliance Global Partners
Jeffrey Kraws - Crystal Research
Robert LeBoyer - NOBLE Capital Markets
Jason Kolbert - Dawson James
Vernon Bernardino - H.C. Wainwright
Operator
Good afternoon, and welcome, everyone, to the GeoVax Fourth Quarter 2023 Corporate Update Call. My name is Desiree, and I will facilitate today's call.
With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Dr. Mark Newman, Chief Scientific Officer; Dr. Kelly McKee, Chief Medical Officer; and Dr. John Sharkey, Vice President, Business Development. [Operator Instructions] As a reminder, this conference is being recorded.
At this time, I am turning the call over to Max Gadicke of SternIR.
Max Gadicke
Thank you. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including weather.
GeoVax can develop and manufacture its product candidates with the desired characteristics in a timely manner and such products will be safe for human use. GeoVax's vaccines will effectively prevent targeted infections in humans. GeoVax's product candidates will receive regulatory approvals and necessaries to be licensed and marketed. GeoVax raises required capital to complete development of its products. There is development of competitive products that may be more effective or easier to use than GeoVax's products.
GeoVax will be able to enter into favorable manufacturing and distribution agreements and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at Risk Factors in GeoVax's Form 10-K.
It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.
David Dodd
Good afternoon, and thank you for participating in the GeoVax corporate update call.
Last year, and more specifically, during the fourth quarter, we successfully advanced our developments, focused on the two Phase 2 clinical stage products while also advancing other critically important initiatives.